Three Strikes But Not Out: GSK Maneuvers Through A Third R&D Setback
This article was originally published in The Pink Sheet Daily
Executive Summary
GlaxoSmithKline’s decision to end a Phase III trial testing the cancer immunotherapy MAGE-A3 in NSCLC is no surprise, following disappointing results in two trials, but coupled with other disappointing R&D news it put more pressure on the company to deliver on its respiratory launches.
You may also be interested in...
Avastin Ovarian Cancer Approval Brings Some Clarity On PFS Endpoint
New claim for platinum-resistant recurrent disease based on a median 3.4-month improvement in progression-free survival – with favorable trends in overall survival, overall response rate and duration of response – confirms agency’s willingness to entertain a progression endpoint in this tumor type.
Post-Novartis, GSK Assures Immuno-Oncology R&D Running At Full Speed
Working with partners, GSK aims to have at least two new cancer immunotherapies in the clinic by mid-2015, says Axel Hoos, the former BMS exec who developed the checkpoint grandfather Yervoy.
Post-Novartis, GSK Assures Immuno-Oncology R&D Running At Full Speed
Working with partners, GSK aims to have at least two new cancer immunotherapies in the clinic by mid-2015, says Axel Hoos, the former BMS exec who developed the checkpoint grandfather Yervoy.